Company intelligence / Profile preview

Welwaze Medical

Doral, Florida, United Stateswelwaze.com ↗

Ownership: Private
Employees: ~31
Development stage: Other

Overview

Celbrea TMDTM has been validated in clinical trials with over 5,000 patients across the US, Europe, and South America. It supports early detection of breast abnormalities by measuring temperature differences on the surface of the breasts. The technology provides adjunctive support to routine physical exams and mammography. The companion mobile app uses computer vision and machine learning for risk analysis.

Therapeutic areas: Oncology
Modalities: DeviceSoftware (AI-powered health monitoring device and app)
Industry: Physiological Monitoring

Partnerships

Not specified in available sources; notable recognition from Novartis Innovation Week award suggests industry engagement but no formal partnerships listed.

Beyond the preview

Go deeper on Welwaze Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Welwaze Medical.

Explore the full profile